Multidisciplinary Cancer Investigation

en The Prognostic Value of HER1 R497K in the Management of Patients with Breast Cancer Supportive and Palliative Care Original/Research Article <div style="text-align: justify;">Introduction: Breast cancer is among the leading causes of cancer death in women. Despite extensive efforts to identify novel prognostic and predictive clinical biomarkers, a very small number of markers have been reported as risk stratification biomarkers (e.g., BRCA1/2 and HER2). The substitution of arginine with lysine in codon 497 of HER1 497 has been suggested as a potential marker in breast cancer. This study attempted to explore the association between HER1 497 gene polymorphisms with pathological and clinical information of breast cancer patients. Methods: 110 breast cancer patients were recruited followed by genomic DNA extraction and genotyping using Taqman-PCR and sequencing. The associations of this genetic variant were evaluated with breast cancer risk and pathological information of patients.  Results: Our data showed that 9.43% of cases had AA genotype, while these frequencies in AC and CC genotypes were 77.35% and 13.20%, respectively. Moreover, we found that 78.4% of breast cancer patients with M0 had AA+AC genotypes, while 21.6% of CC cases had M0 status. Furthermore, 22.7% of these cases with CC genotype had N0/1. Interestingly, we observed that most of the patients with CC genotype had lower HER2 expression. Conclusions: Our finding showed the potential association of CC genotype of HER1 497 with the prognosis of patients with breast cancer. Further studies are warranted to explore the prognostic value of this marker in a larger and multi-center setting in breast cancer.</div>   Breast Neoplasms, Genotype, Biomarkers 17 22 http://mcijournal.com/browse.php?a_code=A-10-609-1&slc_lang=en&sid=1 Masoomeh Baderi masoomeh_bader@yahoo.com 10031947532846003535 10031947532846003535 No 1) Department of Basic Sciences, Payam-e Noor University of Mashhad, Mashhad, Iran 2) Cancer Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran Soodabeh ShahidSales shahidsales@yahoo.com 10031947532846003536 10031947532846003536 No Cancer Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran Kazem Anvari Anvarim@yahoo.com 10031947532846003537 10031947532846003537 No Cancer Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran Hassan Ramshini RamshiniH@yahoo.com 10031947532846003538 10031947532846003538 No Department of Biology, Payam-e Noor University, Branch of Sabzevar, Sabzevar, Iran Shima Mehrabadi sh-mehrabadi@razi.tums.ac.ir 10031947532846003539 10031947532846003539 No Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran Abolfazal Nosrati Tirkani Nosrati-tirkani@yahoo.com 10031947532846003540 10031947532846003540 No Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran Mehrane Mehramiz M.Mehramiz@yahoo.com 10031947532846003541 10031947532846003541 No Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran Seyed Mahdi Hassanian HassanianMehr@mums.ac.ir 10031947532846003542 10031947532846003542 No 1) Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran 2) Department of Medical Biochemistry, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran Amir Avan amir_avan200@yahoo.com 10031947532846003543 10031947532846003543 Yes 1) Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran 2) Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran